dr. glaspy: the angiogenesis-inhibiting drugs... there are a lot of them out there. some of them have exciting pre-clinical data. they're in early clinical trials, and they may sort of change this gameboard a lot for us. then we... get into the realm of experimental treatments, drugs like herceptin, which... attack something that's different about a cancer cell, and make that cell either stop growing, or make it more sensitive to treatment with the other modalities. in 1986, the scientific community learned that a gene involved in regulating cell growth had been discovered -- her2/neu. about the same time, dr. dennis slamon and his team of researchers were extraing dna from discarded cancer tissue, looking for genetic alterations that might be linked to the disease. these are the pieces of the breast tumors. dr. slamon: about 30% of patients who had breast cancer had this particular gene altered, and we recognized that it wasn't something inherited, but it was something that was occurring during the life of the individuals. in a normal cell, they conol the production